Literature DB >> 19574198

Why cerebellar glioblastoma is rare and how that indicates adjunctive use of the FDA-approved anti-emetic aprepitant might retard cerebral glioblastoma growth: a new hypothesis to an old question.

Richard E Kast.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19574198     DOI： 10.1007/s12094-009-0379-x

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


× No keyword cloud information.
  38 in total

1.  Volumetric evaluation of the relations among the cerebrum, cerebellum and brain stem in young subjects: a combination of stereology and magnetic resonance imaging.

Authors:  Nihat Ekinci; Niyazi Acer; Akcan Akkaya; Seref Sankur; Taner Kabadayi; Bünyamin Sahin
Journal:  Surg Radiol Anat       Date:  2008-05-14       Impact factor: 1.246

2.  Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p.

Authors:  Stefan Kneifel; Dominik Cordier; Stephan Good; Mihai C S Ionescu; Anthony Ghaffari; Silvia Hofer; Martin Kretzschmar; Markus Tolnay; Christos Apostolidis; Beatrice Waser; Marlene Arnold; Jan Mueller-Brand; Helmut R Maecke; Jean Claude Reubi; Adrian Merlo
Journal:  Clin Cancer Res       Date:  2006-06-15       Impact factor: 12.531

3.  Gender and age affect NK1 receptors in the human brain - a positron emission tomography study with [18F]SPA-RQ.

Authors:  Mikko J Nyman; Olli Eskola; Jaana Kajander; Tero Vahlberg; Sandra Sanabria; Donald Burns; Richard Hargreaves; Olof Solin; Jarmo Hietala
Journal:  Int J Neuropsychopharmacol       Date:  2006-03-30       Impact factor: 5.176

4.  Detailed immunoautoradiographic mapping of enkephalinase (EC 3.4.24.11) in rat central nervous system: comparison with enkephalins and substance P.

Authors:  H Pollard; M L Bouthenet; J Moreau; E Souil; P Verroust; P Ronco; J C Schwartz
Journal:  Neuroscience       Date:  1989       Impact factor: 3.590

Review 5.  The role of tachykinins via NK1 receptors in progression of human gliomas.

Authors:  C Palma; C A Maggi
Journal:  Life Sci       Date:  2000       Impact factor: 5.037

6.  Individual voxelwise dosimetry of targeted 90Y-labelled substance P radiotherapy for malignant gliomas.

Authors:  Stefan Kneifel; Peter Bernhardt; Helena Uusijärvi; Stephan Good; Ludwig Plasswilm; Carlos Buitrago-Téllez; Jan Müller-Brand; Helmut Mäcke; Adrian Merlo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-31       Impact factor: 9.236

Review 7.  Molecular biology of malignant gliomas.

Authors:  Cristóbal Belda-Iniesta; Javier de Castro Carpeño; Enrique Casado Sáenz; Paloma Cejas Guerrero; Rosario Perona; Manuel González Barón
Journal:  Clin Transl Oncol       Date:  2006-09       Impact factor: 3.405

Review 8.  Repairing brain after stroke: a review on post-ischemic neurogenesis.

Authors:  Charles Wiltrout; Bradley Lang; Yiping Yan; Robert J Dempsey; Raghu Vemuganti
Journal:  Neurochem Int       Date:  2007-05-04       Impact factor: 3.921

9.  L-Thyroxine vs. 3,5,3'-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase.

Authors:  Hung-Yun Lin; Mingzeng Sun; Heng-Yuan Tang; Cassie Lin; Mary K Luidens; Shaker A Mousa; Sandra Incerpi; George L Drusano; Faith B Davis; Paul J Davis
Journal:  Am J Physiol Cell Physiol       Date:  2009-01-21       Impact factor: 4.249

Review 10.  Substance P and its receptors -- a potential target for novel medicines in malignant brain tumour therapies (mini-review).

Authors:  Marzena Łazarczyk; Ewa Matyja; Andrzej Lipkowski
Journal:  Folia Neuropathol       Date:  2007       Impact factor: 2.038
View more
  6 in total

Review 1.  Glioblastoma chemotherapy adjunct via potent serotonin receptor-7 inhibition using currently marketed high-affinity antipsychotic medicines.

Authors:  R E Kast
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

2.  Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells.

Authors:  Richard E Kast; Susana Ramiro; Sandra Lladó; Salvador Toro; Rafael Coveñas; Miguel Muñoz
Journal:  J Neurooncol       Date:  2015-11-24       Impact factor: 4.130

Review 3.  The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer.

Authors:  Marisa Rosso; Miguel Muñoz; Michael Berger
Journal:  ScientificWorldJournal       Date:  2012-04-01

4.  Distinct genomic profile and specific targeted drug responses in adult cerebellar glioblastoma.

Authors:  Hee Jin Cho; Junfei Zhao; Sang Won Jung; Erik Ladewig; Doo-Sik Kong; Yeon-Lim Suh; Yeri Lee; Donggeon Kim; Sun Hee Ahn; Mykola Bordyuh; Hyun Ju Kang; Jason K Sa; Yun Jee Seo; Sung Tae Kim; Do Hoon Lim; Yun-Sik Dho; Jung-Il Lee; Ho Jun Seol; Jung Won Choi; Woong-Yang Park; Chul-Kee Park; Raul Rabadan; Do-Hyun Nam
Journal:  Neuro Oncol       Date:  2019-01-01       Impact factor: 12.300

Review 5.  A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.

Authors:  Richard E Kast; John A Boockvar; Ansgar Brüning; Francesco Cappello; Wen-Wei Chang; Boris Cvek; Q Ping Dou; Alfonso Duenas-Gonzalez; Thomas Efferth; Daniele Focosi; Seyed H Ghaffari; Georg Karpel-Massler; Kirsi Ketola; Alireza Khoshnevisan; Daniel Keizman; Nicolas Magné; Christine Marosi; Kerrie McDonald; Miguel Muñoz; Ameya Paranjpe; Mohammad H Pourgholami; Iacopo Sardi; Avishay Sella; Kalkunte S Srivenugopal; Marco Tuccori; Weiguang Wang; Christian R Wirtz; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2013-04

6.  CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.

Authors:  Richard E Kast; Georg Karpel-Massler; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2014-09-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.